Your browser is no longer supported. Please, upgrade your browser.
Settings
DARE Dare Bioscience, Inc. daily Stock Chart
DARE [NASD]
Dare Bioscience, Inc.
Index- P/E- EPS (ttm)-1.68 Insider Own0.80% Shs Outstand16.61M Perf Week2.23%
Market Cap15.45M Forward P/E- EPS next Y-0.83 Insider Trans- Shs Float13.52M Perf Month-7.93%
Income-16.70M PEG- EPS next Q-0.23 Inst Own7.70% Short Float1.70% Perf Quarter14.80%
Sales- P/S- EPS this Y56.20% Inst Trans-1.01% Short Ratio0.19 Perf Half Y1.00%
Book/sh0.33 P/B2.82 EPS next Y-4.30% ROA- Target Price4.50 Perf Year-19.91%
Cash/sh0.21 P/C4.41 EPS next 5Y- ROE- 52W Range0.60 - 3.25 Perf YTD30.88%
Dividend- P/FCF- EPS past 5Y33.50% ROI- 52W High-71.39% Beta2.28
Dividend %- Quick Ratio4.20 Sales past 5Y- Gross Margin- 52W Low54.98% ATR0.07
Employees19 Current Ratio4.20 Sales Q/Q- Oper. Margin- RSI (14)33.49 Volatility5.55% 6.51%
OptionableNo Debt/Eq0.00 EPS Q/Q- Profit Margin- Rel Volume0.15 Prev Close0.89
ShortableYes LT Debt/Eq0.00 EarningsMay 14 AMC Payout- Avg Volume1.23M Price0.93
Recom- SMA20-5.89% SMA50-21.79% SMA200-4.96% Volume178,069 Change4.37%
May-20-19 11:14PM  Edited Transcript of DARE earnings conference call or presentation 14-May-19 8:30pm GMT Thomson Reuters StreetEvents
May-14-19 04:00PM  Daré Bioscience Reports First Quarter 2019 Financial Results and Company Update GlobeNewswire
May-08-19 08:00AM  Daré Bioscience Announces the Publication of a Pharmacokinetics Study of DARE-FRT1, a Potential Therapy for Preterm Birth and Fertility, in Drug Delivery and Translational Research GlobeNewswire
May-07-19 08:00AM  Daré Bioscience to Host First Quarter 2019 Financial Results and Company Update Conference Call and Webcast GlobeNewswire
Apr-15-19 10:26AM  Edited Transcript of DARE earnings conference call or presentation 4-Apr-19 12:30pm GMT Thomson Reuters StreetEvents
08:00AM  Dr. James Simon, Award-Winning Physician, Presents on Ovaprene® as a Promising Novel Non-Hormonal Contraceptive Method in Clinical Development GlobeNewswire
Apr-09-19 09:30AM  DARE: Pipeline Timelines Intact. Several Development-Related Milestones Upcoming Zacks Small Cap Research -22.71%
08:45AM  Daré Bioscience, Inc. Prices Underwritten Public Offering of Common Stock GlobeNewswire
Apr-08-19 04:28PM  Daré Bioscience, Inc. Announces Proposed Public Offering of Common Stock GlobeNewswire
08:00AM  Daré Bioscience Announces Publication of Pharmacokinetics Study of DARE-HRT1, a Potential Hormone Replacement Therapy, in the Journal of Pharmaceutical Sciences GlobeNewswire
Apr-01-19 04:30PM  Daré Bioscience, Inc. Regains Listing Compliance on Nasdaq GlobeNewswire
08:00AM  Daré Bioscience, Inc. to Host Business Update and Full Year 2018 Financial Results Conference Call and Webcast GlobeNewswire
Mar-29-19 08:00AM  World-renowned Scientist, Described as the Edison of Medicine by Forbes Magazine, Dr. Robert Langer Joins Daré Bioscience Scientific Advisory Board GlobeNewswire
Mar-18-19 02:00PM  Four Healthcare Stocks Heating Up On Monday ACCESSWIRE +128.26%
01:12PM  Dare Bioscience stock rockets to pace all gainers after positive findings from VVA treatment study MarketWatch
08:30AM  Daré Bioscience, Inc. to Present at the 31st Annual ROTH Conference GlobeNewswire
08:00AM  Daré Bioscience Announces Publication of Positive Clinical Findings for Vaginal Administration of Tamoxifen for the Treatment of VVA GlobeNewswire
Mar-11-19 08:00AM  Daré Bioscience receives notification of second award from the National Institutes of Health Eunice Kennedy Shriver National Institute of Child Health and Human Development for the development of Ovaprene® GlobeNewswire
Mar-05-19 08:00AM  Daré Bioscience, Inc. to Present at the Cowen 39th Annual Healthcare Conference GlobeNewswire
Feb-28-19 08:00AM  Daré Bioscience, Inc. to Present at the 16th Annual BIO Asia International Conference GlobeNewswire
Feb-05-19 08:00AM  Daré Bioscience, Inc. to Present at the 2019 BIO CEO & Investor Conference GlobeNewswire
Jan-02-19 08:00AM  Daré Bioscience Provides Update for Investors on Development Programs and Anticipated 2019 Milestones GlobeNewswire
Dec-25-18 02:18PM  What Kind Of Investor Owns Most Of Daré Bioscience, Inc. (NASDAQ:DARE)? Simply Wall St.
Dec-19-18 04:33PM  Edited Transcript of DARE earnings conference call or presentation 13-Nov-18 1:30pm GMT Thomson Reuters StreetEvents
Dec-17-18 03:45PM  DARE: DARE Adds Late-Stage Bacterial Vaginosis Candidate To Ever-Expanding Womens Health Pipeline Zacks Small Cap Research -15.94%
Dec-06-18 09:15AM  New Healthcare Trends Pushing Stocks Higher On Thursday ACCESSWIRE +15.16%
08:00AM  Daré Bioscience, Inc. Announces Licensing and Global Rights to Novel Phase III Product Candidate for the Treatment of Bacterial Vaginosis GlobeNewswire
Dec-03-18 11:15AM  DARE: Ovaprene PCT Continues. TS Content Validity Study, Thermographic Study Underway Zacks Small Cap Research
Nov-29-18 08:00AM  Daré Bioscience, Inc. Announces Initiation of Content Validity Study for Sildenafil Cream, 3.6%, a Potential Therapy for Female Sexual Arousal Disorder GlobeNewswire
Nov-27-18 08:00AM  Daré Bioscience, Inc. Announces Enrollment in Thermography Feasibility Study with Sildenafil Cream, 3.6%, a Potential Therapy for Female Sexual Arousal Disorder GlobeNewswire
Nov-13-18 07:30AM  Daré Bioscience Provides Business Update and Announces Third Quarter Financial Results GlobeNewswire
Nov-06-18 08:00AM  Daré to Host Third Quarter 2018 Financial Results Conference Call and Webcast GlobeNewswire
Oct-30-18 08:00AM  Daré Announces Two Late-Breaking Abstracts to be Presented at the American Association of Pharmaceutical Scientists (AAPS) in Washington D.C. GlobeNewswire
Oct-23-18 08:00AM  Daré Bioscience, Inc. to Present at the Dawson James Small Cap Growth Conference GlobeNewswire
Oct-15-18 08:00AM  Daré Bioscience, Inc. to Present an Overview of Novel Intra-Vaginal Ring (IVR) Technologies at the Partnership Opportunities in Drug Delivery (PODD) Meeting Held in Boston, MA October 17th 18th GlobeNewswire +17.68%
Oct-10-18 08:00AM  Daré Bioscience, Inc. to Present at the 2018 BIO Investor Forum GlobeNewswire
Sep-19-18 09:45AM  DARE: Upcoming Milestones Inc FDA Feedback on Topical Sildenafil FSAD Program Zacks Small Cap Research
Sep-17-18 08:00AM  Greg Matz Joins Daré Bioscience Board of Directors GlobeNewswire
Aug-30-18 08:00AM  Daré Bioscience, Inc. to Present at the H.C. Wainwright 20th Annual Global Investment Conference GlobeNewswire
Aug-02-18 08:00AM  Daré Bioscience, Inc. to Present at the Canaccord Genuity 38th Annual Growth Conference GlobeNewswire
Jul-23-18 08:10AM  Daré Bioscience, Growing Through Collaborations, Male Contraceptive, Analysts Target ACCESSWIRE
Jul-16-18 08:00AM  Daré Bioscience, Inc. Announces Asset Transfer Agreement with Hydra Biosciences, Inc. for CatSper Contraceptive Target GlobeNewswire +10.33%
Jun-18-18 07:20AM  Free Daily Technical Summary Reports on Dermira and Three Other Biotech Stocks ACCESSWIRE
Jun-06-18 08:00AM  Daré Bioscience, Inc. Expands Leadership Team, Appointing David Friend, Ph.D. to Chief Scientific Officer GlobeNewswire
Jun-05-18 07:30AM  DARE: Initiating Coverage of DARE With $6.75/share Price Target Zacks Small Cap Research
Jun-04-18 08:00AM  Daré Bioscience, Inc. Expands Leadership Team, Appointing Mary Jarosz, RPh, to Global Head of Regulatory Affairs GlobeNewswire
May-25-18 05:37PM  Daré Bioscience Inc (NASDAQ:DARE): When Will It Breakeven? Simply Wall St.
May-16-18 08:00AM  EY Announces that Sabrina Martucci Johnson, CEO of Daré Bioscience, Inc., is an Entrepreneur Of The Year® 2018 Award Finalist in San Diego GlobeNewswire
May-15-18 08:00AM  Daré Bioscience, Inc. Announces Trial Initiation for Ovaprene® Non-Hormonal Monthly Contraceptive Candidate GlobeNewswire
May-08-18 08:00AM  Daré Bioscience, Inc. Expands Leadership Team, Appointing John Fair to Chief Business Officer GlobeNewswire -8.73%
May-07-18 08:00AM  Daré Bioscience, Inc. Enters into Agreement to Acquire Product to Address Vulvar and Vaginal Atrophy in Hormone Receptor-Positive Breast Cancer Patients GlobeNewswire +10.59%
Apr-30-18 08:00AM  Daré Bioscience announces funding award to further the development of Ovaprene from the National Institutes of Health Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) GlobeNewswire +7.82%
Apr-26-18 08:10AM  Todays Research Reports on Stocks to Watch: Dare Bioscience and ACADIA ACCESSWIRE
Apr-25-18 08:00AM  Daré Bioscience, Inc. Enters into Exclusive Worldwide License Agreement for Juniper Pharmaceuticals Intravaginal Ring (IVR) Technology Platform GlobeNewswire +56.69%
Apr-13-18 07:20AM  Blog Exposure - BiondVax Pharma Initiated NIH-Sponsored Phase-2 Clinical Trial of M-001 in the US ACCESSWIRE
Apr-11-18 08:00AM  Jessica Grossman, M.D., Joins Daré Bioscience Board of Directors GlobeNewswire
Apr-02-18 04:05PM  Daré Bioscience, Inc. Reports 2017 Financial Results and Provides Business Update GlobeNewswire
12:15PM  Dare Bioscience, Inc. to Host Earnings Call ACCESSWIRE
Mar-29-18 08:30AM  Daré Bioscience, Inc. to Announce Full Year 2017 Financial Results and Host a Live Conference Call and Webcast on Monday, April 2, 2018 GlobeNewswire
Mar-12-18 08:00AM  Daré Bioscience Announces Exclusive Development and Option Agreement with Orbis Biosciences for Long-acting Injectable Contraceptive GlobeNewswire
Mar-05-18 08:00AM  Daré Bioscience, Inc. To Participate in the 30th Annual ROTH Conference GlobeNewswire
Feb-27-18 08:00AM  Daré Bioscience, Inc. To Participate in the LD Micro Virtual Conference GlobeNewswire -5.15%
Feb-26-18 08:10AM  Daré Bioscience, Developing Products for Women, Analysts Target, Pipeline Review ACCESSWIRE
Feb-15-18 11:06AM  Daré Bioscience, Inc. Announces Effective License and Collaboration Agreement for Topical Sildenafil for Female Sexual Arousal Disorder GlobeNewswire
Feb-13-18 09:18AM  Daré Bioscience, Inc. to raise approximately $10.25 million GlobeNewswire -39.78%
08:30AM  Todays Research Reports on Trending Tickers: Dare Bioscience and MannKind ACCESSWIRE
Feb-12-18 08:57PM  Daré Bioscience, Inc. Announces Proposed Public Offering of Common Stock GlobeNewswire +50.00%
08:00AM  Daré Bioscience, Inc. Enters into License and Collaboration Agreement for a Product with the Potential to Receive the First FDA Approval for Female Sexual Arousal Disorder GlobeNewswire
Feb-06-18 08:00AM  Daré Bioscience, Inc. to Present at the 2018 BIO CEO & Investor Conference GlobeNewswire +7.37%
Jan-10-18 09:01AM  Sabrina Martucci Johnson Joins Aethlon Medical's Board of Directors PR Newswire
Dec-08-17 07:03PM  Who Are The Major Shareholders Of Daré Bioscience Inc (DARE)? Simply Wall St. +9.17%
Dec-04-17 08:00AM  Daré Bioscience, Inc. to Present at the LD Micro 10th Annual Main Event Conference GlobeNewswire
Nov-30-17 01:05PM  With An ROE Of 177.59%, Has Daré Bioscience Incs (DARE) Management Done A Good Job? Simply Wall St.
Oct-20-17 09:56AM  Daré Bioscience Inc (DARE): Is Healthcare Attractive Relative To NasdaqCM Peers? Simply Wall St.
Oct-10-17 08:30AM  Daré Bioscience, Inc. to Present at the 2017 BIO Investor Forum GlobeNewswire
Sep-07-17 08:30AM  Daré Bioscience, Inc. to Present at the 19th Annual Rodman & Renshaw Global Investment Conference GlobeNewswire
Aug-30-17 08:30AM  Daré Bioscience, Inc. to Present at the Liolios 6th Annual Gateway Conference GlobeNewswire
Aug-15-17 08:30AM  Daré Bioscience, Inc. CEO Featured in San Diego Business Journal Article on Women Founders GlobeNewswire
Dare Bioscience, Inc., a clinical-stage biopharmaceutical company, focuses on developing and marketing women's reproductive health products in the United States. The company intends to develop therapies in the areas of contraception, vaginal health, sexual health, and fertility. Its product portfolio includes Ovaprene, a non-hormonal monthly contraceptive vaginal ring; Sildenafil Cream, a novel cream formulation of sildenafil to treat female sexual arousal disorder utilizing the active ingredient in Viagra; DARE-BV1, a hydrogel formulation of clindamycin phosphate 2% to treat bacterial vaginosis via a single application; and DARE-HRT1, a combination of bio-identical estradiol and progesterone intravaginal ring for hormone replacement therapy. The company has license agreement with ADVA-Tec, Inc. to develop and commercialize Ovaprene for human contraceptive use; and license and collaboration agreement with Strategic Science and Technologies-D, LLC and Strategic Science Technologies, LLC to develop and commercialize indications for women related to female sexual dysfunction and/or female reproductive health. The company is headquartered in San Diego, California.